Nearly 18 million people die each year from cardiovascular diseases (CVD), making them the world’s leading cause[1] of death. Driven by factors like dyslipidemia, hypertension, and metabolic syndrome, these risks demand new solutions. Retatrutide, a novel triple receptor agonist (GLP-1, GIP, glucagon), shows promise by promoting weight loss and improving lipid and blood pressure profiles, […]